secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0000950170-24-120154
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum issues $20M promissory note to Pfizer at 8% interest for deferred milestone payment
--------------------------------------------------------------------------------

- FDA approved ORLYNVAH (sulopenem) on Oct 25 for uncomplicated UTIs in adult women.
- $20M regulatory milestone payment triggered under 2015 Pfizer license agreement.
- Company elected to defer payment for 2 years (until Oct 25, 2026) via promissory note.
- Note bears 8% annual interest compounded daily; prepayable without penalty.
- Upon change of control during deferral, Pfizer may accelerate full payment plus interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024120154/0000950170-24-120154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024120154/itrm-20241028.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer